Clinical and Laboratory Features of 16 Chinese VEXAS Syndrome Patients

16 male VEXAS syndrome patients were identified from a retrospective analysis of 4512 patients with hematologic abnormalities at a Chinese academic hospital between June 2023 and July 2024. The dataset, authored by Xiang Ren and last updated in April 2026, profiles patient demographics, clinical presentations, bone marrow findings, and UBA1 gene mutation types.

Use Cases

• Characterizing the clinical spectrum of VEXAS syndrome based on described features like anemia, lymphopenia, and multiorgan involvement
• Analyzing the prevalence of specific UBA1 gene mutations (e.g., p.M41V) based on the reported variant frequencies
• Investigating associations between bone marrow morphology (e.g., vacuoles) and clinical outcomes based on the described pathological findings
• Studying treatment response patterns to corticosteroids, immunosuppressants, androgens, and erythropoiesis-stimulating agents based on the reported therapeutic outcomes

Strengths

• Data is derived from a screening cohort of 4512 consecutive patients, providing context for prevalence
• Includes detailed phenotypic data on 16 patients, covering demographics, lab results, bone marrow pathology, and genetic variants
• Specific mutation frequencies are provided, with canonical UBA1 variants detected in 81.3% (13/16) of patients

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data is from a single-center case series, which may reflect institutional bias

Provenance

Source

Retrospective analysis at a Chinese academic hospital, authored by Xiang Ren and shared on figshare.

Collection Method

Retrospective case series analysis of patient records.

Time Range

Patient data collected between June 2023 and July 2024.

Freshness

Last updated 2026-04-16 05:19:14; freshness should be verified

Geography

China (single-center study).